Trial Profile

A Phase 2 Study to Investigate the Safety and Efficacy of ABBV-105 and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 24 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

15 Jun 2024 Results analyzing Modular Gene Expression Changes in Patients with Systemic Lupus Erythematosus, presented at the 25th Annual Congress of the European League Against Rheumatism
15 Nov 2023 Results assessing efficacy and safety of ABBV-599 and upadacitinib monotherapy in adults with moderately to severely active Systemic Lupus Erythematosus,were presented at the ACR Convergence 2023.
15 Nov 2023 Results assessing response to upadacitinib and ABBV-599 of immunologic pathways associated with systemic lupus erythematosus pathogenesis, presented at the ACR Convergence 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com